PTPRC and neoplasm: A single dose of CD45-targeted IL-12 concentrated in the tumor, followed by a single dose of CD45-targeted IL-15 accumulated in both the tumor and the TDLNs, altered T cell programming in the TDLNs, expanding tumor-specific CD8+ T cells with a transcriptional signature mirroring effective responses to acute viral infection.